Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 13/20 | 0.36 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | QPCT | Q16769 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7657867 | 0.92 | BDKRB2 (0.34) | CAMK2DBDKRB2PDE4BPDE4DPIM1 | |
| SCHEMBL7652454 | 0.92 | CAMK2D (0.36) | CAMK2DBDKRB2PDE4BPDE4DPIM1 | |
| SCHEMBL7666596 | 0.91 | BDKRB2 (0.33) | CAMK2DBDKRB2PDE4BPDE4DCRHBP | |
| SCHEMBL7663724 | 0.91 | BDKRB2 (0.33) | CAMK2DBDKRB2PDE4BPDE4DCRHBP | |
| SCHEMBL8365278 | 0.91 | CAMK2D (0.37) | CAMK2DBDKRB2GSK3BKDR | |
| SCHEMBL7658242 | 0.87 | MAOB (0.38) | CAMK2DPDE4BPDE4DKDR | |
| SCHEMBL8365275 | 0.86 | CAMK2D (0.37) | CAMK2DBDKRB2PDE4BPDE4DPIM1 | |
| SCHEMBL7658933 | 0.86 | PDE4B (0.46) | CAMK2DPDE4BPDE4DGSK3BKDR | |
| Acetic Acid SCHEMBL7657331 | 0.83 | CAMK2D (0.38) | CAMK2DBDKRB2PIM1GSK3BKDR | |
| SCHEMBL7664768 | 0.83 | CAMK2D (0.46) | CAMK2DPIM1GSK3BKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458792-B1 | MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. | ASTRAZENECA AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1071683-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999046264-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 1999-09-16 | — | — | WO | disclosed |